Zacks Research Issues Pessimistic Estimate for ENSC Earnings

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Investment analysts at Zacks Research dropped their Q3 2026 EPS estimates for Ensysce Biosciences in a report released on Friday, August 14th. Zacks Research analyst B. Sorensen now expects that the company will earn ($0.19) per share for the quarter, down from their prior estimate of $0.04. The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($1.27) per share. Zacks Research also issued estimates for Ensysce Biosciences’ Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($1.09) EPS and FY2027 earnings at ($0.06) EPS.

Ensysce Biosciences (NASDAQ:ENSC) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.20). The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.20 million. Ensysce Biosciences had a negative net margin of 280.53% and a negative return on equity of 2,550.30%.

A number of other brokerages have also recently commented on ENSC. Weiss Ratings reissued a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Friday, July 17th. Wall Street Zen raised Ensysce Biosciences to a “hold” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Ensysce Biosciences Price Performance

NASDAQ:ENSC opened at $0.39 on Thursday. The stock’s 50 day simple moving average is $0.31 and its two-hundred day simple moving average is $0.39. Ensysce Biosciences has a 1 year low of $0.23 and a 1 year high of $2.75. The company has a market cap of $7.55 million, a price-to-earnings ratio of -0.14 and a beta of 0.84.

Hedge Funds Weigh In On Ensysce Biosciences

Several hedge funds have recently made changes to their positions in ENSC. Adage Capital Partners GP L.L.C. increased its holdings in shares of Ensysce Biosciences by 100.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after purchasing an additional 75,000 shares during the period. DRW Securities LLC grew its stake in shares of Ensysce Biosciences by 42.4% during the 4th quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock worth $91,000 after purchasing an additional 29,336 shares during the period. Citadel Advisors LLC purchased a new position in Ensysce Biosciences in the third quarter valued at $34,000. Finally, Virtu Financial LLC purchased a new position in shares of Ensysce Biosciences in the 3rd quarter valued at about $34,000. 5.63% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Ensysce Biosciences

In related news, Director Bob G. Gower acquired 400,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were purchased at an average price of $0.49 per share, for a total transaction of $196,000.00. Following the completion of the acquisition, the director directly owned 916,740 shares in the company, valued at $449,202.60. The trade was a 77.41% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.80% of the company’s stock.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.